Ying chang Xing

Dr. Ying chang Xing


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Experimental Cell Research
Verified
Journal Article
Closed access
CZChuanyan Zhao
Chuanyan Zhao
ZCZhuyun Chen
Zhuyun Chen
XXXueqiang Xu
Xueqiang Xu
XAXiaofei An
Xiaofei An
SDSuyan Duan
Suyan Duan
YYYanggang Yuan
Yanggang Yuan

11 June 2019 in Free Radical Research
Verified
Journal Article
Closed access
LWLin Wu
Lin Wu
QLQing Li
Qing Li
SLSimeng Liu
Simeng Liu
XAXiaofei An
Xiaofei An
ZHZhimin Huang
Zhimin Huang
YXYing chang Xing
Ying chang Xing
Ischemia/reperfusion (IR) is a common cause of acute kidney injury (AKI). However, effective therapies for IR-induced AKI are lacking. Hyperoside is an active constituent in the flowers of Abelmoschus manihot (L.) Medic, which is a traditional Chinese herbal medicine for the treatment of various ischemic brain and heart diseases. Our previous study demonstrated that hyperoside inhibited adriamycin induced podocyte injury both in vivo and in vitro. The aim of this study is to investigate the effect of hyperoside in IR-induced AKI. In mice, pretreatment of hyperoside could markedly attenuate IR-induced AKI, tubular cell apoptosis and oxidative stress in the kidneys. Meanwhile, we found hyperoside inhibited IR-induced mitochondrial fission by suppressing OMA1 mediated proteolysis of OPA1. Consistently, in human proximal tubular epithelial cells, hyperoside might inhibit CoCl2-induced mitochondrial fission, oxidative stress and apoptosis by regulating OMA1-OPA1 axis. Taken together, our results support the idea that OMA1-OPA1 mediated mitochondrial fission can be used for the prevention of AKI. Hyperoside might have novel therapeutic potential in the treatment of AKI.

7 March 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
SLSimeng Liu
Simeng Liu
YYYanggang Yuan
Yanggang Yuan
YXYi Xue
Yi Xue
YXYing chang Xing
Ying chang Xing
BZBo Zhang
Bo Zhang
Podocytes are a crucial cellular component in maintaining the glomerular filtration barrier, and their injury is the major determinant in the development of albuminuria and diabetic kidney disease (DKD). Podocytes are rich in mitochondria and heavily dependent on them for energy to maintain normal functions. Emerging evidence suggests that mitochondrial dysfunction is a key driver in the pathogenesis of podocyte injury in DKD. Impairment of mitochondrial function results in an energy crisis, oxidative stress, inflammation, and cell death. In this review, we summarize the recent advances in the molecular mechanisms that cause mitochondrial damage and illustrate the impact of mitochondrial injury on podocytes. The related mitochondrial pathways involved in podocyte injury in DKD include mitochondrial dynamics and mitophagy, mitochondrial biogenesis, mitochondrial oxidative phosphorylation and oxidative stress, and mitochondrial protein quality control. Furthermore, we discuss the role of mitochondria-associated membranes (MAMs) formation, which is intimately linked with mitochondrial function in podocytes. Finally, we examine the experimental evidence exploring the targeting of podocyte mitochondrial function for treating DKD and conclude with a discussion of potential directions for future research in the field of mitochondrial dysfunction in podocytes in DKD.

21 February 2017 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
LWLin Wu
Lin Wu
MCMingyu Chen
Mingyu Chen
HMHuijuan Mao
Huijuan Mao
NWNingning Wang
Ningning Wang
BZBo Zhang
Bo Zhang
YXYing chang Xing
Ying chang Xing
Glucocorticoids (GCs) are commonly used in the treatment of nephrotic syndrome. However, high doses and long periods of GC therapy can result in severe side effects. The present study aimed to selectively deliver albumin‑methylprednisolone (MP) nanoparticles towards glomerular podocytes, which highly express the specific neonatal Fc receptor (FcRn) of albumin. Bovine serum albumin (BSA) was labeled with a fluorescent dye and linked with modified MP via an amide bond. The outcome nanoparticle named BSA633‑MP showed a uniform size with a diameter of approximately 10 nm and contained 12 drug molecules on average. The nanoconjugates were found to be stable at pH 7.4 and acid‑sensitive at pH 4.0, with approximately 72% release of the MP drug after 48 h of incubation. The nanoparticle demonstrated a 36‑fold uptake in receptor‑specific cellular delivery in the FcRn‑expressing human podocytes compared to the uptake in the non-FcRn-expressing control cells. Co‑localization further confirmed that uptake of the nanoconjugates involved receptor‑mediated endocytosis followed by lysosome associated transportation. In vitro cellular experiments indicated that the BSA633‑MP ameliorated puromycin aminonucleoside‑induced podocyte apoptosis. Moreover, in vivo fluorescence molecular imaging showed that BSA633-MP was mainly accumulated in the liver and kidney after intravenous dosing for 24 h. Collectively, this study may provide an approach for the effective and safe therapy of nephrotic syndrome.

1 May 2019 in Carbohydrate Polymers
Verified
Journal Article
Closed access
HLHailun Li
Hailun Li
ZYZhuan Yan
Zhuan Yan
QXQiangping Xiong
Qiangping Xiong
XCXiaoling Chen
Xiaoling Chen
YLYongtao Lin
Yongtao Lin
YXYing chang Xing
Ying chang Xing

2 September 2018 in Free Radical Research
Verified
Journal Article
Closed access
XLXi Liu
Xi Liu
WCWei Cao
Wei Cao
JQJia Qi
Jia Qi
QLQing Li
Qing Li
MZMin Zhao
Min Zhao
YXYing chang Xing
Ying chang Xing
Leonurine, a major bioactive component from Herba Leonuri, shows therapeutic potential in several diseases, including diabetes, cardiovascular disease, bovine mastitis and depression. In kidney, it was reported that leonurine was performing a protective effect in both acute kidney injury and renal fibrosis mice models. The aim of this study is to investigate the effect of leonurine in podocyte injury. In the mice model of adriamycin (ADR) -induced nephropathy, the application of leonurine significantly prevented early kidney damage, macrophage infiltration and proteinuria. Meanwhile, leonurine suppressed ADR-induced podocyte injury and reactive oxygen species (ROS) production. Consistent to in vivo results, leonurine prevented ADR-induced podocyte injury and ROS production in cultured human podocytes. All these results suggested that leonurine might suppress ADR-induced podocyte injury via inhibiting oxidative stress. Leonurine might be a novel therapeutic drug for prevention of glomerular diseases.